^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Lymphoma |
| Drug: | tolinapant (ASTX660) (XIAP antagonist, cIAP1 antagonist, cIAP2 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tolinapant, a Non-Peptidomimetic Antagonist of Inhibitors of Apoptosis Proteins, cIAP1/2 and XIAP, in Combination with the Hypomethylating Agents, Azacytidine and Decitabine Are Highly Synergistic in in Vitro Models of T Cell Lymphoma
Published date:
11/03/2022
Excerpt:
TCL lines demonstrated a range of sensitivities to tolinapant with the most sensitive cell line, ALK+ ALCL SUP-M2, having an IC50 as low as 20 nM ± 1 nM while a resistant CTCL cell line HH had an IC50 of over 20 µM.
DOI:
10.1182/blood-2022-169906
Source:
Title:
The combination of the IAP antagonist, tolinapant and hypomethylating agents (HMA) is highly synergistic in in vitro models of T-cell lymphoma (TCL).
Published date:
05/26/2022
Excerpt:
A panel of 10 human TCL lines were tested in proliferation assays (CellTiterGlo) for sensitivity to tolinapant in the presence or absence of 10 ng/ml of TNFα….TCL Lines demonstrated varying sensitivities to tolinapant with the most sensitive cell line, ALK+ ALCL SUP-M2, having an IC50 as low as 20 nM ± 1 nM...
DOI:
10.1200/JCO.2022.40.16_suppl.e15088
